News
SURPASS-CVOT evaluated the efficacy and safety of tirzepatide compared with dulaglutide in adults with T2D and a confirmed ASCVD.
Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach for many obese Americans.
The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...
Measuring insulin levels in saliva is a non-invasive way to determine if someone is at risk of developing type 2 diabetes and ...
Medical professionals observe that GLP-1 medications like Ozempic show promise for treating rheumatoid arthritis alongside other inflammatory conditions.
Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...
18h
GlobalData on MSNTargeting energy expenditure: the next wave of obesity drugs
Biotechs investigate mitochondria-targeting drugs to claim a share in the weight loss drug market dominated by GLP-1RAs.
Bristol-Myers Squibb Company beats revenue forecasts & raises 2025 guidance. Click for key BMY catalysts, risks, and outlook ...
8h
News-Medical.Net on MSNChatGPT helps speed up patient screening for clinical trials
Health discovers that ChatGPT can accelerate patient screening for clinical trials, showing promise in reducing delays and ...
Injectable peptide (CNW Group/Health Canada (HC)) Summary. Product: Unauthorized injectable peptide drugs. Issue: Health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results